المؤلفون: E. E. Grishina, G. R. Setdikova, I. D. Kim, A. M. Bogatyrev, I. A. Loskutov, E. R. Eremeeva

المصدر: Российский офтальмологический журнал, Vol 15, Iss 2, Pp 11-17 (2022)

مصطلحات موضوعية: secondary ophthalmic hypertension, pathogenesis, intraocular pressure, uveal melanoma, neovascularization, Ophthalmology, RE1-994

وصف الملف: electronic resource

Relation: https://roj.igb.ru/jour/article/view/984; https://doaj.org/toc/2072-0076; https://doaj.org/toc/2587-5760

URL الوصول: https://doaj.org/article/d51a09c3cd61428492a8fb01ec5c3b02

المؤلفون: I. V. Mikhailov, E. R. Eremeeva, A. A. Glazkov, I. M. Telezhnikova, G. R. Setdikova, A. S. Balkanov, И. В. Михайлов, Е. Р. Еремеева, А. А. Глазков, И. М. Тележникова, Г. Р. Сетдикова, А. С. Балканов

المصدر: Siberian journal of oncology; Том 23, № 5 (2024); 47-58 ; Сибирский онкологический журнал; Том 23, № 5 (2024); 47-58 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: периневральная инвазия, negative HER2-neu status, HER2-low status, tumor-associated macrophages, perineural invasion, негативный HER2-neu статус, HER2-low статус, опухоль-ассоциированные макрофаги

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3266/1270; Pernas S., Tolaney S.M. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat. 2022; 193(2): 281–91. doi:10.1007/s10549-022-06575-7.; Denkert C., Seither F., Schneeweiss A., Link T., Blohmer J.U., Just M., Wimberger P., Forberger A., Tesch H., Jackisch C., Schmatloch S., Reinisch M., Solomayer E.F., Schmitt W.D., Hanusch C., Fasching P.A., Lübbe K., Solbach C., Huober J., Rhiem K., Marmé F., Reimer T., Schmidt M., Sinn B.V., Janni W., Stickeler E., Michel L., Stötzer O., Hahnen E., Furlanetto J., Seiler S., Nekljudova V., Untch M., Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8): 1151–61. doi:10.1016/S1470-2045(21)00301-6.; Jin J., Li B., Cao J., Li T., Zhang J., Cao J., Zhao M., Wang L., Wang B., Tao Z., Hu X. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023; 21(1): 360. doi:10.1186/s12967-023-04076-9.; Вторушин С.В., Крахмаль Н.В., Завалишина Л.Э., Кузнецова О.А., Москвина Л.В., Франк Г.А. Определение HER2-статуса карцином различных локализаций. Архив патологии. 2023; 85(6): 31–46. doi:10.17116/patol20238506131.; Schlam I., Tolaney S.M., Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023; 67: 116–23. doi:10.1016/j.breast.2023.01.005.; Moy B., Wolff A.C., Rumble R.B., Allison K.H., Carey L.A. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023; 19(8): 547–50. doi:10.1200/OP.23.00047.; Vaziri Fard E., Ali Y., Wang X.I., Saluja K., H Covinsky M., Wang L., Zhang S. Tumor-Infltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infltrating Lymphocytes in Invasive Breast Carcinoma. Am J Clin Pathol. 2019; 152(5): 656–65. doi:10.1093/ajcp/aqz088.; García-Martínez E., Gil G.L., Benito A.C., González-Billalabeitia E., Conesa M.A., García García T., García-Garre E., Vicente V., Ayala de la Peña F. Tumor-infltrating immune cell profles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014; 16(6): 488. doi:10.1186/s13058-014-0488-5.; Skriver S.K., Jensen M.B., Knoop A.S., Ejlertsen B., Laenkholm A.V. Tumour-infltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Res. 2020; 22(1): 46. doi:10.1186/s13058-020-01285-8.; Salgado R., Denkert C., Campbell C., Savas P., Nuciforo P., Aura C., de Azambuja E., Eidtmann H., Ellis C.E., Baselga J., PiccartGebhart M.J., Michiels S., Bradbury I., Sotiriou C., Loi S. TumorInfltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015; 1(4): 448–54. doi:10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015; 1(4): 544. doi:10.1001/jamaoncol.2015.1805. Erratum in: JAMA Oncol. 2015; 1(8): 1172. doi:10.1001/jamaoncol.2015.4229. Nucifero, Paolo [corrected to Nuciforo, Paolo]. Erratum in: JAMA Oncol. 2019; 5(1): 122. doi:10.1001/jamaoncol.2018.5678.; Perez E.A., Ballman K.V., Tenner K.S., Thompson E.A., Badve S.S., Bailey H., Baehner F.L. Association of Stromal Tumor-Infltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol. 2016; 2(1): 56–64. doi:10.1001/jamaoncol.2015.3239.; Fernandez-Martinez A., Pascual T., Singh B., Nuciforo P., Rashid N.U., Ballman K.V., Campbell J.D., Hoadley K.A., Spears P.A., Pare L., Brasó-Maristany F., Chic N., Krop I., Partridge A., Cortés J., Llombart-Cussac A., Prat A., Perou C.M., Carey L.A. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs TumorInfltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023; 9(4): 490–9. doi:10.1001/jamaoncol.2022.6288.; Pruneri G., Gray K.P., Vingiani A., Viale G., Curigliano G., Criscitiello C., Láng I., Ruhstaller T., Gianni L., Goldhirsch A., Kammler R., Price K.N., Cancello G., Munzone E., Gelber R.D., Regan M.M., Colleoni M. Tumor-infltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016; 158(2): 323–31. doi:10.1007/s10549-016-3863-3.; Киселевский М.В., Власенко Р.Я., Заботина Т.Н., Кадагидзе З.Г. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология. 2019; 40(1): 73–82. doi:10.24411/0206-4952-2019-11009.; Lundgren C., Bendahl P.O., Ekholm M., Fernö M., Forsare C., Krüger U., Nordenskjöld B., Stål O., Rydén L. Tumour-infltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020; 22(1): 140. doi:10.1186/s13058-020-01364-w.; Gwak J.M., Jang M.H., Kim D.I., Seo A.N., Park S.Y. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One. 2015; 10(4). doi:10.1371/journal.pone.0125728.; Mehraj U., Qayoom H., Mir M.A. Prognostic signifcance and targeting tumor-associated macrophages in cancer: new insights and future perspectives. Breast Cancer. 2021; 28(3): 539–55. doi:10.1007/s12282-021-01231-2.; Hendry S., Salgado R., Gevaert T. et al. Assessing Tumor-infltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017; 24(5): 235–51. doi:10.1097/PAP.0000000000000162.; Wei C., Yang C., Wang S., Shi D., Zhang C., Lin X., Liu Q., Dou R., Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019; 18(1): 64. doi:10.1186/s12943-019-0976-4.; Anderson S., Bartow B.B., Siegal G.P., Huang X., Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Res Treat. 2023; 201(3): 437–46. doi:10.1007/s10549-023-07020-z.; van den Ende N.S., Nguyen A.H., Jager A., Kok M., Debets R., van Deurzen C.H.M. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int J Mol Sci. 2023; 24(3): 2969. doi:10.3390/ijms24032969.; Takada K., Kashiwagi S., Asano Y., Goto W., Kouhashi R., Yabumoto A., Morisaki T., Shibutani M., Takashima T., Fujita H., Hirakawa K., Ohira M. Prediction of lymph node metastasis by tumor-infltrating lymphocytes in T1 breast cancer. BMC Cancer. 2020; 20(1): 598. doi:10.1186/s12885-020-07101-y.; Jeong H., Hwang I., Kang S.H., Shin H.C., Kwon S.Y. TumorAssociated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer. J Breast Cancer. 2019; 22(1): 38–51. doi:10.4048/ jbc.2019.22.e5.; Kashyap D., Bal A., Irinike S., Khare S., Bhattacharya S., Das A., Singh G. Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of Breast Cancer. Appl Immunohistochem Mol Morphol. 2023; 31(8): 533–43. doi:10.1097/PAI.0000000000001139.; Allison E., Edirimanne S., Matthews J., Fuller S.J. Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis. Oncol Ther. 2023; 11(1): 27–48. doi:10.1007/s40487-022-00214-3.; Zhao X., Qu J., Sun Y., Wang J., Liu X., Wang F., Zhang H., Wang W., Ma X., Gao X., Zhang S. Prognostic signifcance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18): 30576–86. doi:10.18632/oncotarget.15736.; Muraro E., Martorelli D., Turchet E., Miolo G., Scalone S., Comaro E., Talamini R., Mastorci K., Lombardi D., Perin T., Carbone A., Veronesi A., Crivellari D., Dolcetti R. A diferent immunologic profle characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011; 13(6). doi:10.1186/bcr3060.; Mohamed R.F., Abdelhameed D.H., Mohamed M.A. Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer. JCO Glob Oncol. 2023; 9. doi:10.1200/GO.22.00269.; Wang X., Zhang L., Zhang X., Luo J., Wang X., Chen X., Yang Z., Mei X., Yu X., Zhang Z., Guo X., Shao Z., Ma J. Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Breast Cancer Res Treat. 2021; 190(2): 277–86. doi:10.1007/s10549-021-06378-2.; Mittendorf E.A., Ballman K.V., McCall L.M., Yi M., Sahin A.A., Bedrosian I., Hansen N., Gabram S., Hurd T., Giuliano A.E., Hunt K.K. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015; 33(10): 1119–27. doi:10.1200/JCO.2014.57.2958.; https://www.siboncoj.ru/jour/article/view/3266

الاتاحة: https://www.siboncoj.ru/jour/article/view/3266
https://doi.org/10.21294/1814-4861-2024-23-5-47-58

المؤلفون: A I Evsikov, D N Grekov, Paklina Ov, N V Chizhova, E R Eremeeva, D L Rotin

المصدر: Arkhiv patologii. 82(6)

مصطلحات موضوعية: 0301 basic medicine, Pathology, medicine.medical_specialty, Autopsy, Thyroid Carcinoma, Anaplastic, Pathology and Forensic Medicine, Metastasis, Anaplastic thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Rare case, medicine, Humans, Anaplastic carcinoma, Thyroid Neoplasms, Stage (cooking), Aged, business.industry, Thyroid, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e70b1061175cc3f94fafd0e3c7050b3
https://pubmed.ncbi.nlm.nih.gov/33274628